Workday, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Workday, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jan 31, 2018 | $582.48M | Mar 14, 2018 |
| FY2018 | Oct 31, 2017 | $555.39M | Mar 14, 2018 |
| FY2018 | Jul 31, 2017 | $525.32M | Mar 14, 2018 |
| FY2018 | Apr 30, 2017 | $479.86M | Mar 14, 2018 |
| FY2018 | Jan 31, 2017 | $439.58M | Mar 14, 2018 |
| FY2018 | Oct 31, 2016 | $413.52M | Mar 14, 2018 |
| FY2018 | Jul 31, 2016 | $373.66M | Mar 14, 2018 |
| FY2018 | Apr 30, 2016 | $347.68M | Mar 14, 2018 |
| FY2017 | Jan 31, 2016 | $323.43M | Mar 20, 2017 |
| FY2017 | Oct 31, 2015 | $305.27M | Mar 20, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $9.55B | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | $8.45B | Mar 6, 2026 |
| FY2026 | Jan 31, 2024 | $7.26B | Mar 6, 2026 |
| FY2025 | Jan 31, 2023 | $6.22B | Mar 11, 2025 |
| FY2024 | Jan 31, 2022 | $5.14B | Mar 8, 2024 |
| FY2021 | Jan 31, 2021 | $1.13B | Mar 2, 2021 |
| FY2021 | Oct 31, 2020 | $1.11B | Mar 2, 2021 |
| FY2021 | Jul 31, 2020 | $1.06B | Mar 2, 2021 |
| FY2021 | Apr 30, 2020 | $1.02B | Mar 2, 2021 |
| FY2021 | Jan 31, 2020 | $976.30M | Mar 2, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $693.00M | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | $526.00M | Mar 6, 2026 |
| FY2026 | Jan 31, 2024 | $1.38B | Mar 6, 2026 |
| FY2025 | Jan 31, 2023 | ($367.00M) | Mar 11, 2025 |
| FY2024 | Jan 31, 2022 | $29.00M | Mar 8, 2024 |
| FY2021 | Jan 31, 2021 | ($71.71M) | Mar 2, 2021 |
| FY2021 | Oct 31, 2020 | ($24.34M) | Mar 2, 2021 |
| FY2021 | Jul 31, 2020 | ($28.02M) | Mar 2, 2021 |
| FY2021 | Apr 30, 2020 | ($158.37M) | Mar 2, 2021 |
| FY2021 | Jan 31, 2020 | ($127.96M) | Mar 2, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $721.00M | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | $415.00M | Mar 6, 2026 |
| FY2026 | Jan 31, 2024 | $183.00M | Mar 6, 2026 |
| FY2025 | Jan 31, 2023 | ($222.00M) | Mar 11, 2025 |
| FY2024 | Jan 31, 2022 | ($116.00M) | Mar 8, 2024 |
| FY2021 | Jan 31, 2021 | ($73.31M) | Mar 2, 2021 |
| FY2021 | Oct 31, 2020 | ($14.08M) | Mar 2, 2021 |
| FY2021 | Jul 31, 2020 | ($16.75M) | Mar 2, 2021 |
| FY2021 | Apr 30, 2020 | ($144.46M) | Mar 2, 2021 |
| FY2021 | Jan 31, 2020 | ($146.10M) | Mar 2, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $2.68B | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | $2.63B | Mar 6, 2026 |
| FY2026 | Jan 31, 2024 | $2.46B | Mar 6, 2026 |
| FY2025 | Jan 31, 2023 | $2.25B | Mar 11, 2025 |
| FY2024 | Jan 31, 2022 | $1.88B | Mar 8, 2024 |
| FY2023 | Jan 31, 2021 | $1.72B | Feb 27, 2023 |
| FY2022 | Jan 31, 2020 | $1.55B | Feb 28, 2022 |
| FY2021 | Jan 31, 2019 | $1.21B | Mar 2, 2021 |
| FY2020 | Jan 31, 2018 | $910.58M | Mar 3, 2020 |
| FY2019 | Jan 31, 2017 | $680.53M | Mar 18, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $2.94B | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | $2.46B | Mar 6, 2026 |
| FY2026 | Jan 31, 2024 | $2.15B | Mar 6, 2026 |
| FY2025 | Jan 31, 2023 | $1.66B | Mar 11, 2025 |
| FY2024 | Jan 31, 2022 | $1.65B | Mar 8, 2024 |
| FY2023 | Jan 31, 2021 | $1.27B | Feb 27, 2023 |
| FY2022 | Jan 31, 2020 | $864.60M | Feb 28, 2022 |
| FY2021 | Jan 31, 2019 | $606.66M | Mar 2, 2021 |
| FY2020 | Jan 31, 2018 | $465.73M | Mar 3, 2020 |
| FY2019 | Jan 31, 2017 | $350.63M | Mar 18, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $162.00M | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | $269.00M | Mar 6, 2026 |
| FY2026 | Jan 31, 2024 | $232.00M | Mar 6, 2026 |
| FY2025 | Jan 31, 2023 | $364.00M | Mar 11, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $18.07B | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | $17.98B | Mar 6, 2026 |
| FY2025 | Jan 31, 2024 | $16.45B | Mar 11, 2025 |
| FY2024 | Jan 31, 2023 | $13.49B | Mar 8, 2024 |
| FY2023 | Jan 31, 2022 | $10.50B | Feb 27, 2023 |
| FY2022 | Jan 31, 2021 | $8.72B | Feb 28, 2022 |
| FY2021 | Jan 31, 2020 | $6.82B | Mar 2, 2021 |
| FY2020 | Jan 31, 2019 | $5.52B | Mar 3, 2020 |
| FY2019 | Jan 31, 2018 | $4.95B | Mar 18, 2019 |
| FY2018 | Jan 31, 2017 | $3.27B | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $10.27B | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | $8.94B | Mar 6, 2026 |
| FY2025 | Jan 31, 2024 | $8.37B | Mar 11, 2025 |
| FY2024 | Jan 31, 2023 | $7.90B | Mar 8, 2024 |
| FY2023 | Jan 31, 2022 | $5.96B | Feb 27, 2023 |
| FY2022 | Jan 31, 2021 | $5.44B | Feb 28, 2022 |
| FY2021 | Jan 31, 2020 | $4.33B | Mar 2, 2021 |
| FY2020 | Jan 31, 2019 | $3.56B | Mar 3, 2020 |
| FY2019 | Jan 31, 2018 | $3.37B | Mar 18, 2019 |
| FY2018 | Jan 31, 2017 | $1.99B | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $7.81B | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | $9.03B | Mar 6, 2026 |
| FY2026 | Jan 31, 2024 | $8.08B | Mar 6, 2026 |
| FY2025 | Jan 31, 2023 | $5.59B | Mar 11, 2025 |
| FY2024 | Jan 31, 2022 | $4.54B | Mar 8, 2024 |
| FY2023 | Jan 31, 2021 | $3.28B | Feb 27, 2023 |
| FY2022 | Jan 31, 2020 | $2.49B | Feb 28, 2022 |
| FY2021 | Jan 31, 2019 | $1.96B | Mar 2, 2021 |
| FY2020 | Jan 31, 2018 | $1.58B | Mar 3, 2020 |
| FY2019 | Jan 31, 2017 | $1.28B | Mar 18, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $5.23B | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | $3.48B | Mar 6, 2026 |
| FY2025 | Jan 31, 2024 | $2.85B | Mar 11, 2025 |
| FY2024 | Jan 31, 2023 | $2.84B | Mar 8, 2024 |
| FY2023 | Jan 31, 2022 | $2.84B | Feb 27, 2023 |
| FY2022 | Jan 31, 2021 | $1.82B | Feb 28, 2022 |
| FY2021 | Jan 31, 2020 | $1.82B | Mar 2, 2021 |
| FY2020 | Jan 31, 2019 | $1.38B | Mar 3, 2020 |
| FY2019 | Jan 31, 2018 | $159.38M | Mar 18, 2019 |
| FY2019 | Jan 31, 2017 | $107.66M | Mar 18, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($512.00M) | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | ($1.21B) | Mar 6, 2026 |
| FY2025 | Jan 31, 2024 | ($1.73B) | Mar 11, 2025 |
| FY2024 | Jan 31, 2023 | ($3.11B) | Mar 8, 2024 |
| FY2023 | Jan 31, 2022 | ($2.74B) | Feb 27, 2023 |
| FY2022 | Jan 31, 2021 | ($2.91B) | Feb 28, 2022 |
| FY2021 | Jan 31, 2020 | ($2.63B) | Mar 2, 2021 |
| FY2020 | Jan 31, 2019 | ($2.15B) | Mar 3, 2020 |
| FY2019 | Jan 31, 2018 | ($1.73B) | Mar 18, 2019 |
| FY2018 | Jan 31, 2017 | ($1.41B) | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $1.50B | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | $1.54B | Mar 6, 2026 |
| FY2026 | Jan 31, 2024 | $2.01B | Mar 6, 2026 |
| FY2025 | Jan 31, 2023 | $1.89B | Mar 11, 2025 |
| FY2024 | Jan 31, 2022 | $1.53B | Mar 8, 2024 |
| FY2023 | Jan 31, 2021 | $1.38B | Feb 27, 2023 |
| FY2022 | Jan 31, 2020 | $731.14M | Feb 28, 2022 |
| FY2021 | Jan 31, 2019 | $638.55M | Mar 2, 2021 |
| FY2020 | Jan 31, 2018 | $1.13B | Mar 3, 2020 |
| FY2019 | Jan 31, 2017 | $539.92M | Mar 18, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jan 31, 2024 | $2.98B | Mar 8, 2024 |
| FY2024 | Jan 31, 2023 | $2.98B | Mar 8, 2024 |
| FY2023 | Jan 31, 2022 | $1.84B | Feb 27, 2023 |
| FY2022 | Jan 31, 2021 | $1.80B | Feb 28, 2022 |
| FY2021 | Jan 31, 2020 | $1.26B | Mar 2, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 2 | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | 1 | Mar 6, 2026 |
| FY2026 | Jan 31, 2024 | 5 | Mar 6, 2026 |
| FY2025 | Jan 31, 2023 | (1) | Mar 11, 2025 |
| FY2024 | Jan 31, 2022 | 0 | Mar 8, 2024 |
| FY2023 | Jan 31, 2021 | (1) | Feb 27, 2023 |
| FY2022 | Jan 31, 2020 | (2) | Feb 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 2 | Mar 6, 2026 |
| FY2026 | Jan 31, 2025 | 1 | Mar 6, 2026 |
| FY2026 | Jan 31, 2024 | 5 | Mar 6, 2026 |
| FY2025 | Jan 31, 2023 | (1) | Mar 11, 2025 |
| FY2024 | Jan 31, 2022 | 0 | Mar 8, 2024 |
| FY2023 | Jan 31, 2021 | (1) | Feb 27, 2023 |
| FY2022 | Jan 31, 2020 | (2) | Feb 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Jan 31, 2012 | 36.00M | Mar 22, 2013 |